Demographic characteristics of participants eligible for LTBI screening
| Demographic | N=114 | % |
| Age (years) | ||
| ≤25 | 12 | 10.5 |
| 26–35 | 32 | 28.1 |
| 36+ | 70 | 61.4 |
| Sex | ||
| Female | 64 | 56.1 |
| Male | 50 | 43.9 |
| Origin | ||
| Europe, North America, Caribbean, Australia | 13 | 11.4 |
| Middle East, North Africa | 2 | 1.8 |
| Other Asia | 8 | 7.0 |
| Indian Subcontinent | 3 | 2.6 |
| Sub-Saharan Africa | 77 | 67.5 |
| Central and Southern America | 11 | 9.6 |
| BCG vaccinated | ||
| Yes | 87 | 76.3 |
| No | 9 | 7.9 |
| Unknown | 18 | 15.8 |
| TST (mm) | ||
| ≥5 | 6 | 5.3 |
| <5 | 14 | 12.2 |
| Not done | 94 | 82.5 |
| CD4 count | ||
| 0–199 | 14 | 12.3 |
| 200–500 | 60 | 52.6 |
| >500 | 40 | 35.1 |
| Viral load | ||
| <50 | 49 | 43.0 |
| 50–1000 | 24 | 21.1 |
| >1000 | 41 | 36.0 |
| HAART therapy | ||
| Yes | 72 | 63.2 |
| No | 42 | 36.8 |
HAART, highly active antiretroviral therapy; LTBI, latent tuberculosis infection; TST, tuberculin skin test.